Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anti-VEGF monoclonal antibody versus bevacizumab with oxaliplatin and fluoropyrimidine as first-line treatment for metastatic colorectal cancer
CTR20242804Phase 3Active
- Sponsor
- Beijing Luzhu Biotechnology
- Start
- Jul 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of bevacizumab, humanized anti-VEGF monoclonal antibody in metastatic colorectal adenocarcinoma (mCRC), sponsored by Beijing Luzhu Biotechnology. Started Jul 2024; status: active.
02
Drugs
bevacizumabhumanized anti-VEGF monoclonal antibody
03
Conditions
metastatic colorectal adenocarcinoma (mCRC)
Beyond the preview
Go deeper on CTR20242804.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20242804.